The Research Priority Area supports a "collaborative matrix," bringing together diverse groups of investigators, trainees and research groups from nine different colleges across the university campus.
UK Neuroscience Professor Greg Gerhardt's new research program will provide answers to questions about the role of neurotransmitters in the progression of Alzheimer’s disease.
Goldstein also is co-director of the Kentucky Neuroscience Institute, co-director of the UK Neuroscience Research Priority Area and interim director of the UK-Norton Healthcare Stroke Care Network. Goldstein’s two-year term on the board of directors begins later this month.
Hyperbaric oxygen treatment (HBO) is a treatment that is now being experimentally studied in adult patients with severe traumatic brain injuries (TBI). Hyperbaric oxygen treatment is a specialized way, using a pressure chamber, to dramatically increase the amount of oxygen delivered to body tissues.
Their work shows that direct measures of brain signatures during mental activity are more sensitive and accurate predictors of memory decline than current standard behavioral testing.
Newly published research has found familiar music can elicit an extended emotional response in patients with Alzheimer’s-type dementia. The findings from this potential new approach were featured in the Journal of Alzheimer’s Disease.
Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.
Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. Van Eldik is one of only six women from UK that have been awarded this honor and she is the first since 1966.
Dr. Peter Nelson, of the University of Kentucky’s Sanders-Brown Center on Aging, has spent the last 15 years in the Commonwealth helping to lead the fight against Alzheimer’s and dementia inducing brain disease.
A $2.9 million grant from the NIH is supporting a multidisciplinary team of UK researchers in continuing their work to find therapeutic strategies to resolve neurovascular inflammation and repair blood-brain barrier dysfunction in epilepsy.
